Chimiothérapie d’induction suivie d’une radiochimiothérapie préopératoire à base de cisplatine, 5FU et panitumumab dans le traitement des cancers oesogastriques avancés et opérables

B Erasme0 sites49 target enrollmentJanuary 7, 2010

Overview

No summary available.

Registry

who.int

Start Date

January 7, 2010

End Date

TBD

Last Updated

11 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

B Erasme

•Locally advanced gastric and EG junction adenocarcinoma with histological proof \> T2a\-N0 (including T2a\-T3\-T4 and N0 or N\+).
•Patient \= 18 years of age.
•Potentially resectable tumor.
•Operable patient without major comorbidities (cardiovascular, pulmonary, neurological).
•Adequate liver, renal and hematological functions.
•Haematology:
•oNeutrophil count \=1\.5x109/L
•oPlatelet count \=100x109/L
•oLeucocyte count \> 3,000/mm
•o Hemoglobin \> 9 g/dL

•Evidence of distant metastases including distant lymph nodes (including supraclavicular, hepatoduodenal, retropancreatic, mesenteric and paraaortic).
•Patients with non operable tumor.
•Prior therapy for upper GI cancer.
•Other histological types than adenocarcinoma.
•History of other primary cancer, unless:
•oCuratively resected non\-melanomatous skin cancer
•oCuratively treated cervical carcinoma in situ
•oOther primary solid tumor curatively treated with no known active disease present and no treatment administered for \= 5 years before enrollment
•Presence of peripheral neuropathy \> grade 1 according to CTCAE.
•Presence of uncontrolled comorbidities.